Cargando…
C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?
From asymptomatic to severe, SARS-CoV-2, causative agent of COVID-19, elicits varying disease severities. Moreover, understanding innate and adaptive immune responses to SARS-CoV-2 is imperative since variants such as Omicron negatively impact adaptive antibody neutralization. Severe COVID-19 is, in...
Autores principales: | Hausburg, Melissa A., Williams, Jason S., Banton, Kaysie L., Mains, Charles W., Roshon, Michael, Bar-Or, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068237/ https://www.ncbi.nlm.nih.gov/pubmed/38013973 http://dx.doi.org/10.1016/j.clicom.2022.05.001 |
Ejemplares similares
-
Clinically distinct COVID-19 cases share notably similar immune response progression: A follow-up analysis
por: Hausburg, Melissa A., et al.
Publicado: (2020) -
The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the “cytokine storm” in COVID-19 patients: a hypothesis
por: Thomas, Gregory, et al.
Publicado: (2020) -
The anti-inflammatory effect of LMWF5A and N-acetyl kynurenine on macrophages: Involvement of aryl hydrocarbon receptor in mechanism of action
por: Rael, Leonard T., et al.
Publicado: (2018) -
LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC
por: Thomas, Gregory, et al.
Publicado: (2020) -
AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC
por: Thomas, Gregory, et al.
Publicado: (2022)